UM
Residential Collegefalse
Status已發表Published
2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy
Yingjun Peng1; Shengyu Fu1
2022-05-26
Source PublicationJournal of Leukocyte Biology
ISSN0741-5400
Volume112Issue:4Pages:823-834
Abstract

Diverse cytokines and their receptors on immune cells constitute a highly complex network in the immune system. Some therapeutic cytokines and their derivatives have been approved for cancer treatment. IL-15 is an immune-regulating cytokine with multiple functions, among which the function of activating the immunity of cancer patients has great potential in cancer immunotherapy. In this review, we introduce the functions of IL-15 and discuss its role in regulating the immune system in different immune cells. Meanwhile, we will address the applications of IL-15 agonists in cancer immunotherapy and provide prospects for the next generation of therapeutic designs. Although many challenges remain, IL-15 agonists offer a new therapeutic option in the future direction of cancer immunotherapy.

KeywordCytokine Il-15 Il-2 Immunotherapy Protein Engineering
DOI10.1002/JLB.5MR0422-506R
URLView the original
Indexed BySCIE
Language英語English
WOS Research AreaCell Biology ; Hematology ; Immunology
WOS SubjectCell Biology ; Hematology ; Immunology
WOS IDWOS:000803428800001
PublisherWILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ
Scopus ID2-s2.0-85130616444
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionUniversity of Macau
Affiliation1.Cancer Centre, Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macao
2.MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macao
First Author AffilicationCancer Centre
Recommended Citation
GB/T 7714
Yingjun Peng,Shengyu Fu. 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy[J]. Journal of Leukocyte Biology, 2022, 112(4), 823-834.
APA Yingjun Peng., & Shengyu Fu (2022). 2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy. Journal of Leukocyte Biology, 112(4), 823-834.
MLA Yingjun Peng,et al."2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy".Journal of Leukocyte Biology 112.4(2022):823-834.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Yingjun Peng]'s Articles
[Shengyu Fu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Yingjun Peng]'s Articles
[Shengyu Fu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Yingjun Peng]'s Articles
[Shengyu Fu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.